- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05208281
Un estudio de múltiples cohortes de seguridad, eficacia, PK y PD de GNR-055 en pacientes con mucopolisacaridosis tipo II
Estudio multicéntrico, abierto y de múltiples cohortes para evaluar la seguridad, la farmacocinética, la farmacodinámica y la eficacia del producto farmacéutico GNR 055 (JSC "GENERIUM", Rusia) en pacientes con mucopolisacaridosis tipo II
This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
GNR-055 is intended for ERT in patient with Mucopolysaccharidosis type II (MPS II), or Hunter syndrome. MPS II is a recessive X-linked inheritance lysosomal storage disease, which is characterized by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (ID2S), caused by a mutation in the ID2S gene. Enzyme deficiency leads to the accumulation of Glycosaminoglycans (GAG) (mainly of heparan and dermatan sulfates) in lysosomes of almost all types of cells of various tissues and organs. The disease is manifested by growth retardation, damage of many organs and systems, severe deformations of bones and joints, gross facial features, pathology of the respiratory and cardiovascular systems, damage to parenchymal organs (hepatosplenomegaly), and hearing impairment. A severe form of the disease occurs with the involvement of the nervous system in the pathological process, including mental retardation, behavior anomalies, and impaired motor function.
GNR-055 is a recombinant modified ID2S capable to penetrate the blood-brain barrier and thus expected to prevent neurodegenerative consequences and the cognitive deficit and to attain a significant improvement in the life quality and expectancy of patients with MPS II.
Study IDB-MPS-II-III is a multicenter, open-label, multi-cohort study to assess safety, PK and PD, and efficacy of GNR-055 in patients of different age groups with MPS II (Hunter syndrome).
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Moscow, Rusia, 119333
- Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences)
-
Saint Petersburg, Rusia, 194100
- Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation
-
Simferopol, Rusia, 295007
- V.I. Vernadsky Crimean Federal University
-
Ufa, Rusia, 450076
- State Budgetary Healthcare Institution Republican Medical Genetic Center
-
Yekaterinburg, Rusia, 620149
- State Autonomous Healthcare Institution of the Sverdlovsk Region Regional Children's Clinical Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Signed inform consent;
- Verified diagnosis of MPS II (Hunter syndrome);
- Naïve patients or patients who have received standard ERT whit idursulfase products;
- No contraindications for lumbar puncture as judged by the Investigator;
- Willingness and ability to follow study procedures.
Exclusion Criteria:
- Clinically pronounced hypersensitivity to ID2S or any other component of the drug product;
- History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation;
- Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment;
- Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his/her participation in the study, or which will influence the safety data analysis in case of the disease/condition exacerbation during the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Adult: GNR-055
GNR-055: 1.0-2.0-3.0 mg/kg |
Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
Otros nombres:
|
|
Experimental: Paediatric: GNR-055 2.0 mg/kg
GNR-055 2.0 mg/kg |
Weekly IV infusion (lyophilized powder) 2.0 mg/kg
Otros nombres:
|
|
Experimental: Paediatric: GNR-055 3.0 mg/kg
GNR-055 3.0 mg/kg |
Weekly IV infusion (lyophilized powder) 3.0 mg/kg
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Baseline to Week 56
|
Safety assessment will be performed based on the subjective complaints, physical examination, assessment of vital signs, laboratory tests, and 12-lead ECG; Incidence of allergic and infusion-related reactions; Incidence of Anti-Drug Antibodies (ADAs) against GNR-055 and their neutralizing activity. |
Baseline to Week 56
|
|
Urine GAG excretion
Periodo de tiempo: Baseline to Week 4, 8, 10, 26, and 52
|
Changes in levels of urine GAG excretion after multiple-dose administration of GNR-055 |
Baseline to Week 4, 8, 10, 26, and 52
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Serum concentration of the GNR-055
Periodo de tiempo: Week 52
|
Assessment of the serum concentration of GNR-055 and calculation of Cmax, AUC, T1/2, Cl et other parameters after multiple-dose administration |
Week 52
|
|
GAG level in CerebroSpinal Fluid (CSF)
Periodo de tiempo: Baseline to Week 6, 10, 26, and 52
|
Changes in levels of CSF GAG after multiple-dose administration of GNR-055 |
Baseline to Week 6, 10, 26, and 52
|
|
Serum GAG level
Periodo de tiempo: Baseline to Week 4, 8, 10, 26, and 52
|
Changes in levels of serum GAG after multiple-dose administration of GNR-055 |
Baseline to Week 4, 8, 10, 26, and 52
|
|
Large joint range of motion
Periodo de tiempo: Week 8, 10, 26, and 52
|
Changes over time in the large joint range of motion after multiple-dose administration of GNR-055 |
Week 8, 10, 26, and 52
|
|
Liver and spleen volumes (MRI)
Periodo de tiempo: Baseline to Week 8, 10, 26, and 52
|
Changes over time in liver and spleen volume according to ultrasound/MRI after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
6-minute walk test
Periodo de tiempo: Baseline to Week 8, 10, 26, and 52
|
Changes over time in the results of the 6-minute walk test after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
Left ventricular mass by EchoCG
Periodo de tiempo: Baseline to Week 8, 10, 26, and 52
|
Changes over time in the left ventricular mass according to Echocardiography (Echo-CG) after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
Lung Forced Vital Capacity (FVC)
Periodo de tiempo: Baseline to Week 8, Week 26, and Week 52
|
Changes over time in FVC according to spirometry after multiple-dose administration of GNR-055 |
Baseline to Week 8, Week 26, and Week 52
|
|
Neurocognitive functions assessment
Periodo de tiempo: Baseline to Week 12, 26, and 52
|
Changes over time in neurocognitive functions after multiple-dose administration of GNR-055 |
Baseline to Week 12, 26, and 52
|
|
Brain white/gray matter structures (MRI)
Periodo de tiempo: Baseline to Week 26, and 52
|
Changes over time in the quantitative MRI brain structure parameters after multiple-dose administration of GNR-055 |
Baseline to Week 26, and 52
|
|
Serum neuromarkers
Periodo de tiempo: Baseline to Week 24, and 52
|
Changes in levels of serum neuromarkers after multiple-dose administration of GNR-055 |
Baseline to Week 24, and 52
|
|
CSF neuromarkers
Periodo de tiempo: Baseline to Week 24, and 52
|
Changes in levels of CSF neuromarkers after multiple-dose administration of GNR-055 |
Baseline to Week 24, and 52
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Oksana A. Markova, MD, MSc, AO GENERIUM
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Enfermedades del Sistema Nervioso
- Enfermedades del tejido conectivo
- Enfermedades Genéticas Congénitas
- Discapacidad intelectual
- Manifestaciones neurológicas
- Desordenes mentales
- Disfunción congnitiva
- Trastornos cognitivos
- Enfermedades metabólicas
- Trastornos neurocognitivos
- Síndrome de Hunter
- Manifestaciones neuroconductuales
- Enfermedades de almacenamiento lisosomal
- Trastornos Heredodegenerativos, Sistema Nervioso
- Enfermedades Genéticas, Ligadas al X
- Mucopolisacaridosis tipo II
- Metabolismo Innato
- Iduronato-2-sulfatasa
- Proteína I2S modificada
- Retraso Mental, Ligado al X
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Metabolismo, errores congénitos
- Muerte
- Enfermedades neurodegenerativas
- Trastornos del neurodesarrollo
- Metabolismo de carbohidratos, errores congénitos
- Mucinosis
- Muerte Súbita
- Mucopolisacaridosis
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Enfermedades de la piel y del tejido conectivo
- Signos y síntomas
- Muerte infantil
- Manifestaciones neurológicas
- Disfunción congnitiva
- Desordenes mentales
- Enfermedades Genéticas Congénitas
- Discapacidad intelectual
- Enfermedades del Sistema Nervioso
- Manifestaciones neuroconductuales
- Enfermedades metabólicas
- Trastornos neurocognitivos
- Mucopolisacaridosis II
- Enfermedades del tejido conectivo
- Enfermedades Genéticas, Ligadas al X
- Trastornos cognitivos
- Enfermedades de almacenamiento lisosomal
- Trastornos Heredodegenerativos, Sistema Nervioso
- Muerte Súbita Infantil
- Discapacidad intelectual ligada al cromosoma X
Otros números de identificación del estudio
- IDB-MPS-II-III
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .